Bitunix Analyst: Houmuz Escalation Continues, Macro Risks Heating Up
BlockBeats News, March 13th, global market risk sentiment continues to be affected by the situation in the Middle East. Trump stated that the U.S. leads global energy production, and an increase in oil prices will bring more benefits to the U.S., but he also emphasized the need to prevent Iran from obtaining nuclear weapons. Meanwhile, Iran's new Supreme Leader, Khamenei, stated that they will continue to block the Strait of Hormuz and keep open the possibility of opening a new front, further raising energy supply risks.
Against the backdrop of an energy shock and escalating conflict, there have been changes in macro policy expectations. The market has significantly reduced its bets on a Fed rate cut this year, with the current expectation for a full-year rate cut of only about 20 basis points, showing that the rate market is reassessing policy uncertainty arising from inflation and geopolitics. At the same time, there are ongoing discussions within the U.S. government on whether to have naval escorts for oil tankers through the Strait of Hormuz, and the market remains highly vigilant about energy supply chain security.
The volatility in the energy market is spilling over to global assets. The International Energy Agency has lowered its oil supply growth expectations and warned that the Middle East conflict could cause the largest supply disruption in history. With oil prices remaining high, global stock markets are generally under pressure, with funds more inclined towards short-term liquidity management rather than long-term risk allocation.
As for the crypto market, the short-term structure of BTC continues to be range-bound. From observing the derivatives liquidation heatmap, the area around 71,300 remains a major level for short liquidation and liquidity concentration above the price, forming short-term resistance; further upwards, the 72,000–73,500 range still has a higher density of short leveraged positions. On the downside, secondary liquidity support can be observed around 69,000, while a more concentrated area of long positions lies around 68,800.
The overall structure shows that in an environment dominated by macro conflict and energy uncertainty, the short-term crypto market continues to be characterized by liquidity sweeps within the range. As long as the short liquidation liquidity above 71,300 is not effectively absorbed, the BTC price is likely to remain in a oscillating structure, waiting for further directional triggers from macro events.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Fed Governor Waller leaves room for hawkishness: More rate hikes are needed to support inflation decline, not necessarily on a monthly basis.
Federal Reserve Governor Waller stated that if the data meets expectations, there will be further interest rate hikes. The core PCE year-on-year rate at 3% is still too high, and the recent monetary policy focus remains on fighting inflation.
Updated: Viatris will acquire pain therapy manufacturer Pacira BioSciences for 1.65 billions dollars.
The second paragraph adds stock information, while the fifth, eighth, and ninth paragraphs provide additional details. Background information is supplemented in the sixth, seventh, tenth, and eleventh paragraphs. Reuters, October 8 – Pharmaceutical company Viatris (VTRS.O) will acquire Pacira BioSciences (PCRX.O) in an all-cash deal worth $1.65 billions, adding two non-opioid painkillers to its portfolio, the companies said on Thursday. Viatris will acquire Pacira at $36.50 per share, representing a 44.8% premium to the latest closing price. Pacira’s stock rose by 44% in premarket trading. Pacira’s non-opioid painkillers, Exparel and Zilretta, generated sales in 2025 of $575.1 millions and $116.6 millions respectively. Exparel is used to relieve acute pain after surgery, and Zilretta is used to treat pain associated with knee osteoarthritis. Viatris stated it expects to expand the reach of these products in selected target markets. Viatris CEO Scott Smith stated, “the addition of these medications creates a synergy with our rapid-acting meloxicam market opportunities, positioning us as a leader in non-opioid pain management.” The US Food and Drug Administration (FDA) is expected to make a decision by December 27 on the approval application for rapid-acting meloxicam for the treatment of moderate to severe acute pain. Viatris plans to finance the acquisition primarily with idle cash, and the remainder through short-term borrowing. The company noted the deal will have minimal impact on its total leverage ratio. In August, Viatris (link) raised its annual adjusted profit forecast, counting on strong brand drug sales and growth in the Chinese market. The pharmaceutical company had previously faced (link) production setbacks in its Indian operations, including a fire at its Nashik plant in western India and increased competition in the generic drug market, raising concerns about the resilience and growth of its core business. The company stated the transaction is expected to close by the end of 2026 and will immediately enhance Viatris’s financial guidance metrics. (For non-native English speakers, Reuters provides automated translations of its reports into several other languages. Since automated translations may contain errors or lack necessary context, Reuters does not guarantee their accuracy and provides them for convenience only. Reuters accepts no liability for any damage or loss caused by the use of automated translation.)
Oppenheimer Adjusts Acuity Price Target to $415 From $440, Maintains Outperform Rating
08:51 AM EDT, 10/08/2026 (MT Newswires) -- Acuity Brands (AYI) has an average rating of overweight and mean price target of $400.57, according to analysts polled by FactSet. (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contact-us)
BUZZ-Pacira BioSciences stock surges on Viatris' $1.65 billion acquisition deal
On October 8, Pacira BioSciences (PCRX.O) shares rose 44% in pre-market trading to $36.30 as Viatris (VTRS.O) announced it will acquire Pacira BioSciences for $1.65 billion in cash, at a price of $36.50 per share. This offer represents a premium of approximately 44.8% over Pacira's last closing price of $25.20. The transaction will add Pacira’s non-opioid pain medications Exparel and Zilretta to Viatris’ product portfolio. Both parties expect the deal to be completed by the end of 2026. As of the previous trading day’s close, PCRX was down 2.6% year-to-date.
Crypto prices
More
